Dysmenorrhea Treatment Market Insights:
Dysmenorrhea Treatment market is projected to be worth USD XX Billion by 2030, registering a CAGR of 8.3% during the forecast period (2022-2030), the market was valued at USD XX Billion in 2021. The type segment is divided into primary dysmenorrhea and secondary dysmenorrhea. Primary dysmenorrhea is expected to dominate the growth of the market owing to its increasing prevalence in women. In treatment type, the NSAID segment is leading the market growth owing to increasing benefits and fast results. In the regional segment, North America leads the growth of the market prevalence of dysmenorrhea and awareness of dysmenorrhea among women.
Dysmenorrhea Treatment Market Dynamics:
Dysmenorrhea Treatment is employed to manage dysmenorrhea symptoms which includes Prostaglandin inhibitors, such as nonsteroidal anti-inflammatory medications (NSAIDs) such as aspirin and ibuprofen to reduce pain, Acetaminophen, and oral contraceptives to inhibitors ovulation.
Driver:
The dysmenorrhea treatment market is driven by the rising prevalence of dysmenorrhea in women. Also, rising Research & Development for the development of pioneering drugs for treating menstrual cramps and improving the early symptoms.
Restraint:
Long-term treatment allied with the side effects and complications and lack of awareness about reproductive health in women and advanced technologies is expected to restrain the dysmenorrhea treatment market’s growth during the forecast period.
Opportunity:
Increasing Research and Development by leading key players such as Pfizer, Inc., Myovant Sciences, and others are anticipated to create lucrative opportunities for the dysmenorrhea treatment market. For instance, Pfizer, Inc. and Myovant Sciences proclaimed positive feedback of phase 3 spirit extension study of once-daily relugolix combination therapy in women with endometriosis in January 2021.
COVID-19 Analysis of Dysmenorrhea Treatment Market:
COVID-19 is an unexpected public health threat that has physically and psychologically impacted millions of individuals. Many people’s psychological well-being has suffered as a result of the outbreak, which has caused loneliness, social isolation, financial pressure, worry and fear of getting the virus, and uncertainty about the future. Psychological and stress discomfort have been shown to have an impact on a woman’s menstrual health. Stress can stimulate the hypothalamic-pituitary-gonadal (HPG) axis and disrupt the neuro-modulatory cascade that regulates gonadotropin-releasing hormone (GnRH), resulting in an irregular menstrual cycle. Changes in menstrual cycles cause more instances of dysmenorrhea, which has a substantial influence on the market. According to a March 2021 study titled “The Impact of the COVID-19 Pandemic on Women’s Reproductive Health,” 46% of women reported a shift in their menstrual cycle, with 30% of new dysmenorrhea instances, since the pandemic began. As a result, COVID-19 has had a considerable influence on the dysmenorrhea treatment market.
Dysmenorrhea Treatment Report Coverage:
| Report Attributes | Report Details |
| Study Timeline | 2016-2030 |
| Market Size in 2030 (USD Billion) | XX |
| CAGR (2022-2030) | 8.3% |
| By Type | Primary Dysmenorrhea, Secondary Dysmenorrhea |
| By Treatment Type | Non-steroidal Anti-inflammatory Drugs (NSAIDs), Hormonal Therapy |
| By geography | North America– (U.S., Canada, Mexico
Europe- (Germany, France, U.K., Russia, Italy, Spain, BENELUX, Rest of Europe) Asia Pacific- (China, Japan, India, South Korea, Australia, ASEAN, Rest of Asia Pacific) Latin America- (Brazil, Argentina, Chile, Rest of Latin America) Middle East and Africa- (GCC, Turkey, Israel, Rest of MEA) |
| Key Players | Novartis AG, Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi, Pfizer Inc., GlaxoSmithKline PLC, Focus Consumer Healthcare, Johnson & Johnson, and Alvogen. |
Dysmenorrhea Treatment Market Segment Analysis:
By Type
The type segment is divided into primary dysmenorrhea and secondary dysmenorrhea. Primary dysmenorrhea affects 45 and 95% of menstruating women and is dominating the type segment of the dysmenorrhea treatment market. In primary dysmenorrhea painful and repeated menstrual cramps occur in the early days before the menstrual cycle or bleeding, and the pain is sensed in the back, lower abdomen, or thigh. Further, the pain is mild to severe and normally lasts for 12 hours to 72 hours. Vomiting, nausea, fatigue, and diarrhea are also observed in this type of condition. Secondary Dysmenorrhea pain is due to an infection or disorder in the woman’s reproductive organs or system where the pain starts in the menstrual cycle and lasts up to common menstrual cramps.
By Treatment Type
NSAIDs such as ibuprofen, diclofenac, meclofenamate, ketoprofen, mefenamic acid, and naproxen are authorized by the Food and Drug Administration (US) for the treating dysmenorrhea symptoms. According to a December 2020 article published in Women’s Health Concern and the British Menopause Society, roughly 80% of dysmenorrhea women have period discomfort during their lives. Premenstrual symptoms such as swelling stomach, sensitive breasts difficulty of focus, bloating, mood swings, clumsiness, and exhaustion are experienced by 40% of women. As a result, dysmenorrhea is treated immediately, which is predicted to boost NSAID use and fuel the segment’s development in the dysmenorrhea treatment market.
By Region
The Dysmenorrhea Treatment market is divided into four regions such as North America, Europe, Asia-Pacific, and Latin America. The market for dysmenorrhea therapy is projected to be dominated by North America. Owing to the rising incidence and prevalence of dysmenorrhea, as well as women’s knowledge of dysmenorrhea, the United States is likely to contribute considerably to this rise. As per research studies carried out in August 2019 titled “The Prevalence and Academic Impact of Dysmenorrhea in 21,573 Young Women: A Systematic Review and Meta-Analysis,” the incidence of dysmenorrhea was 71.1% in the US. The dysmenorrhea frequencies were comparable across both high school and university students, with 75% being substantially higher. The increased frequency of dysmenorrhea raises the need for therapy, propelling the dysmenorrhea treatment market.
Dysmenorrhea Treatment Market Competitive Landscape:
The competitive landscape of the market has been analyzed in the report, along with the detailed profiles of the major players operating in the industry. Further, the surge in Research and Development (R&D), product innovation, various business strategies, and product launches have accelerated the growth of the dysmenorrhea treatment market. Key players in the market include-
- Novartis AG
- Bayer AG
- Abbott Laboratories
- Hoffmann-La Roche Ltd
- Sanofi
- Pfizer Inc.
- GlaxoSmithKline PLC
- Focus Consumer Healthcare
- Johnson & Johnson
- Alvogen
Recent Development
- In 2021, Dr. Reddy’s Laboratories Ltd launched a revised version of the Naproxen Sodium, 220 mg an over-the-counter (OTC) Tablets USP in the US for menstrual cramps, and minor pain.
- In 2021, a part of Yogic Naturals, Femingo introduced a clinically and naturally certified topical application of oil serums for primary dysmenorrhea and PCOS.
Table of Content
- Introduction
- Market Introduction
- Market Research Methodology
- Research Process
- Primary Research
- Secondary Research
- Data Collection Technique
- Data Sources
- Market Estimation Methodology
- Limitations of the Study
- Product Picture of Dysmenorrhea Treatment
- Global Dysmenorrhea Treatment Market: Classification
- Geographic Scope
- Years Considered for the Study
- Research Methodology in brief
- Parent Market Overview
- Overall Dysmenorrhea Treatment Market Regional Demand
- Research Programs/Design
- Market Breakdown and Data Triangulation Approach
- Data Source
- Secondary Sources
- Primary Sources
- Primary Interviews
- Average primary breakdown ratio
- Market Dynamics
- Drivers
- Drivers
- Restraints
- Restraints
- Opportunity
- Impact forces on market dynamics
- Impact forces during the forecast years
- Industry Value Chain
- Upstream analysis
- Downstream analysis
- Distribution Channel
- Direct Channel
- Indirect Channel
- Potential Customers
- Manufacturing/Operational Cost Analysis
- Pricing Analysis by Region
- Key Product Landscape
- Regulatory Analysis
- Porter’s Analysis
- Supplier Power
- Buyer Power
- Substitution Threat
- Threat from New Entry
- Competitive Rivalry
- PESTEL Analysis
- Political Factors
- Economic Factor
- Social Factors
- Technological Factor
- Environmental Factors
- Legal Factor
- Covid-19 impact on Global Economy
- Covid-19 impact on Dysmenorrhea Treatment demand
- Post-Covid Impact on Dysmenorrhea Treatment Market Demand
- Impact Analysis of Russia-Ukraine Conflict
- Drivers
- Global Dysmenorrhea Treatment Market Segmentation, by Revenue (USD Billion), (2022-2030)
- By Product
- Primary Dysmenorrhea
- Secondary Dysmenorrhea
- By Treatment Type
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Hormonal Therapy
- By Product
- Global Dysmenorrhea Treatment Market Overview, By Region
- North America Dysmenorrhea Treatment Market Revenue (USD Billion), by Countries, (2022-2030)
- US
- By Product
- By Treatment Type
- Canada
- Mexico
- US
- Europe Dysmenorrhea Treatment Market Revenue (USD Billion), by Countries, (2022-2030)
- France
- UK
- Spain
- Russia
- Italy
- BENELUX
- Asia Pacific Dysmenorrhea Treatment Market Revenue (USD Billion), by Countries, (2022-2030)
- China
- Japan
- Australia
- South Korea
- India
- ASEAN
- North America Dysmenorrhea Treatment Market Revenue (USD Billion), by Countries, (2022-2030)
- Latin America Dysmenorrhea Treatment Market Revenue (USD Billion), by Countries, (2022-2030)
- Brazil
- Argentina
- Chile
- Middle East and Africa Dysmenorrhea Treatment Market Revenue (USD Billion), by Countries, (2022-2030)
- GCC
- Turkey
- South Africa
- Global Dysmenorrhea Treatment Market Revenue: Competitive Analysis, 2021
- Key strategies by players
- Revenue (USD Billion and %), By manufacturers, 2021
- Player Positioning by Market Players, 2021
- Competitive Analysis
- Novartis AG.
- Business Overview
- Business Financials (USD billion)
- Product Category, Type, and Specification
- Main Business/Business Overview
- Geographical Analysis
- Recent Development
- Swot Analysis
- Bayer AG
- Abbott Laboratories
- Hoffmann-La Roche Ltd
- Sanofi
- Pfizer Inc.
- GlaxoSmithKline PLC
- Focus Consumer Healthcare
- Johnson & Johnson
- Alvogen
- Novartis AG.
- Market Research Findings & Conclusion
Disclaimer
Research Methodology
The Market Research Community offers numerous solutions and its full addition in the research methods to be skilled at each step. We use wide-ranging resources to produce the best outcome for our customers. The achievement of a research development is completely reliant on the research methods implemented by the company. We always faithful to our clients to find opportunities by examining the global market and offering economic insights.Market Research Community are proud of our widespread coverage that encompasses the understanding of numerous major industry domains. Company offers consistency in our research report, we also offers on the part of the analysis of forecast across a range of coverage geographies and coverage. The research teams carry out primary and secondary research to carry out and design the data collection methods.